NasdaqCM - Delayed Quote USD

Onconetix, Inc. (ONCO)

0.1112 +0.0001 (+0.09%)
At close: May 14 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Bruce Harmon Chief Financial Officer 349.38k -- 1958
Dr. Ralph Schiess Ph.D. Interim CEO & Chief Science Officer -- -- 1979
Dr. Brian Price Ph.D. Head of Technology Strategy 126.48k -- --
Mr. Frank A. Jaeger M.A., M.B.A. Senior VP of Marketing & Business Development -- -- 1970
Mr. Andrew D. Skibo Ph.D. Global Head of Biologics Operations -- -- --
Mr. Theodore Scott Yoho Head of Business Development -- -- --
Dr. Ali I. Fattom Ph.D. Head of Science & Discovery -- -- --
Dr. Jay Newmark M.B.A., M.D. Chief Medical Officer -- -- --
Mr. Christian Bruhlmann Chief Strategy Officer & GM of Europe -- -- 1977
Dr. Donald L. Very Jr., Ph.D. Senior VP of Commercial Research & Development -- -- --

Onconetix, Inc.

201 East Fifth Street
Suite 1900
Cincinnati, OH 45202
United States
513 620 4101 https://onconetix.gcs-web.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
12

Description

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Corporate Governance

Onconetix, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 12, 2024 - May 16, 2024
Onconetix, Inc. Earnings Call

Related Tickers

SXTP 60 Degrees Pharmaceuticals, Inc.
0.2200
+1.85%
 
CPMV Mosaic ImmunoEngineering, Inc.
0.4000
0.00%
 
KTTA Pasithea Therapeutics Corp.
6.65
-3.62%
 
FWBI First Wave BioPharma, Inc.
2.9700
-0.67%
 
XCUR Exicure, Inc.
0.4900
+2.45%
 
PHGE BiomX Inc.
0.3460
+1.70%
 
KPRX Kiora Pharmaceuticals, Inc.
0.5001
-1.88%
 
PBLA Panbela Therapeutics, Inc.
0.4408
+8.53%
 
CVKD Cadrenal Therapeutics, Inc.
0.4405
+0.09%
 
KA Kineta, Inc.
0.5200
+0.04%